NO20055314L - 1,2,4-oksadiazolbenzosyreforbindelser og deres anvendelse for nonsense supresjon og behandling av sykdom - Google Patents

1,2,4-oksadiazolbenzosyreforbindelser og deres anvendelse for nonsense supresjon og behandling av sykdom

Info

Publication number
NO20055314L
NO20055314L NO20055314A NO20055314A NO20055314L NO 20055314 L NO20055314 L NO 20055314L NO 20055314 A NO20055314 A NO 20055314A NO 20055314 A NO20055314 A NO 20055314A NO 20055314 L NO20055314 L NO 20055314L
Authority
NO
Norway
Prior art keywords
benzoic acid
disease
acid compounds
oxadiazole benzoic
treatment
Prior art date
Application number
NO20055314A
Other languages
English (en)
Other versions
NO332843B1 (no
NO20055314D0 (no
Inventor
Gary Mitchell Karp
Seongwoo Hwang
Guangming Chen
Neil Gregory Almstead
Young-Choon Moon
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33299886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055314(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of NO20055314D0 publication Critical patent/NO20055314D0/no
Publication of NO20055314L publication Critical patent/NO20055314L/no
Publication of NO332843B1 publication Critical patent/NO332843B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nye 1,2,4-oksadiazolbenzosyreforbindelser, fremgangsmåter for anvendelse og farmasøytiske sanmiensetninger som irmbefatter et 1,2,4-oksadiazolbenzosyrederivat er beskrevet. Fremgangsmåtene inkluderer fremgangsmåter for behandling eller hindring av en sykdom som lindres ved modulering av prematur franslasjonsterminering eller nonsensmediert mRNA-reduksjon, eller som lindrer et eller flere symptomer assosiert dermed.
NO20055314A 2003-04-11 2005-11-10 1,2,4-oksadiazolbenzosyreforbindelser, anvendelse derav og farmasoytisk sammensetning inneholdende en slik forbindelse. NO332843B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46198803P 2003-04-11 2003-04-11
PCT/US2004/011106 WO2004091502A2 (en) 2003-04-11 2004-04-09 1,2,4-oxadiazole benzoic acid compounds

Publications (3)

Publication Number Publication Date
NO20055314D0 NO20055314D0 (no) 2005-11-10
NO20055314L true NO20055314L (no) 2006-01-04
NO332843B1 NO332843B1 (no) 2013-01-21

Family

ID=33299886

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20055314A NO332843B1 (no) 2003-04-11 2005-11-10 1,2,4-oksadiazolbenzosyreforbindelser, anvendelse derav og farmasoytisk sammensetning inneholdende en slik forbindelse.
NO2015002C NO2015002I1 (no) 2003-04-11 2015-02-03 Ataluren (3-[5-(2-fluorfenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2015002C NO2015002I1 (no) 2003-04-11 2015-02-03 Ataluren (3-[5-(2-fluorfenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav

Country Status (29)

Country Link
US (17) US6992096B2 (no)
EP (9) EP4101846B1 (no)
JP (2) JP4851933B2 (no)
KR (1) KR101134188B1 (no)
CN (2) CN104056278B (no)
AU (1) AU2004229487B9 (no)
BE (1) BE2015C025I2 (no)
BR (1) BRPI0409319B8 (no)
CA (1) CA2521992C (no)
CR (1) CR8086A (no)
CY (7) CY1115870T1 (no)
DK (7) DK3103800T3 (no)
EA (1) EA009120B1 (no)
ES (7) ES2887054T3 (no)
FR (1) FR15C0030I2 (no)
HU (7) HUE031794T2 (no)
IL (2) IL171343A (no)
LU (1) LU92698I2 (no)
MA (1) MA27802A1 (no)
MX (1) MXPA05010747A (no)
NO (2) NO332843B1 (no)
NZ (1) NZ543263A (no)
PL (7) PL3345895T3 (no)
PT (7) PT1618098E (no)
SI (7) SI3345895T1 (no)
TR (1) TR201706226T4 (no)
UA (1) UA84420C2 (no)
WO (1) WO2004091502A2 (no)
ZA (1) ZA200508298B (no)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2004001010A2 (en) * 2002-06-21 2003-12-31 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US7927791B2 (en) 2002-07-24 2011-04-19 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mRNA decay
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
EP1799659A1 (en) * 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
AU2012238226B2 (en) * 2005-04-08 2015-05-14 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
PL2402002T3 (pl) * 2005-04-08 2018-11-30 Ptc Therapeutics, Inc. Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop
CN100378084C (zh) * 2005-08-01 2008-04-02 安徽大学 2,5-二芳基取代基-1,3,4-噁二唑衍生物及其合成方法、用途
TWI426905B (zh) * 2006-02-09 2014-02-21 安龍製藥公司 用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物
EP2387995A1 (en) * 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
KR20080109075A (ko) * 2006-04-06 2008-12-16 프로시디온 리미티드 헤테로사이클릭 ｇｐｃｒ 작용제
EP2674428B1 (en) 2006-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20070287699A1 (en) * 2006-05-01 2007-12-13 Virobay, Inc. Antiviral agents
UA99265C2 (ru) * 2006-09-08 2012-08-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)
NZ575795A (en) * 2006-09-25 2012-03-30 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
US8101641B2 (en) * 2006-09-25 2012-01-24 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof
AU2013219243B2 (en) * 2006-10-12 2016-09-08 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
AU2016262645B2 (en) * 2006-10-12 2018-05-17 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
MX2009003909A (es) * 2006-10-12 2009-05-25 Ptc Therapeutics Inc Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora.
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
SG177221A1 (en) * 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
MX2009014001A (es) * 2007-06-22 2010-01-28 Hoffmann La Roche Derivados de isoxazol-imidazol.
CA2685599A1 (en) * 2007-07-23 2009-01-29 Summit Corporation Plc Compounds for treating duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
TWI580356B (zh) 2007-08-13 2017-05-01 孟山都科技有限責任公司 控制植物寄生性線蟲的化合物及方法以及被覆有該化合物之種子
AU2008306886B2 (en) 2007-10-04 2014-01-16 Merck Serono S.A. Oxadiazole diaryl compounds
ES2622423T3 (es) * 2007-10-04 2017-07-06 Merck Serono S.A. Derivados de oxadiazol
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
SI2578571T1 (sl) 2007-11-16 2016-01-29 Vertex Pharmaceuticals Incorporated Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
KR20100097195A (ko) * 2007-12-07 2010-09-02 애보트 게엠베하 운트 콤파니 카게 ５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
EP2231644B1 (de) 2007-12-07 2014-01-15 AbbVie Deutschland GmbH & Co KG 5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
JP5701607B2 (ja) 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
AU2008340113B2 (en) 2007-12-21 2014-01-09 Merck Serono S.A. Triazole oxadiazoles derivatives
CA2708447C (en) * 2007-12-25 2016-05-10 Kissei Pharmaceutical Co., Ltd. Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
EP2732819B1 (en) 2008-02-07 2019-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
NZ616097A (en) 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131954A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
WO2009131956A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US20110293520A1 (en) * 2008-06-09 2011-12-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
WO2010008831A2 (en) * 2008-06-24 2010-01-21 Irm Llc Compounds and methods for modulating g protein-coupled receptors
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
WO2010093650A2 (en) * 2009-02-10 2010-08-19 Divergence, Inc. Compositions and methods for controlling nematodes
JP5620129B2 (ja) * 2009-03-19 2014-11-05 富士フイルム株式会社 光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物
RU2398770C1 (ru) * 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2251437B1 (en) 2009-05-13 2013-12-04 Hannelore Breitenbach-Koller Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
AR076984A1 (es) 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
US9849146B2 (en) * 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
BR122020024226B1 (pt) * 2009-08-05 2021-09-08 International Paper Company Processo para preparar uma folha de polpa fofa
EA024801B1 (ru) 2009-11-13 2016-10-31 Рецептос Ллк Селективные модуляторы рецептора сфингозин-1-фосфата
NZ599913A (en) * 2009-11-13 2014-08-29 Receptos Inc Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
SI2826776T1 (sl) 2010-03-25 2021-02-26 Vertex Pharmaceuticals Incorporated Trdna disperzija amorfne oblike (R)-1(2,2-difluorobenzo(D)(1,3)dioksol-5-il)-N-(1-(2,3-dihidroksipropil) -6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1H-indol-5-il)- ciklopropankarboksamida
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
ES2710854T3 (es) 2010-08-05 2019-04-29 Univ Lille Compuesto útil para el tratamiento de enfermedades mediadas por una mutación sin sentido y composición farmacéutica que comprende dicho compuesto
WO2012027247A2 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US20140094465A1 (en) * 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR101314488B1 (ko) * 2011-09-08 2013-10-07 중앙대학교 산학협력단 신경줄기세포 분화조절제용 신규 옥사디아졸 유도체 및 이의 의학적 용도
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2828249B1 (en) 2012-03-23 2018-10-10 The Regents of The University of California Premature-termination-codons readthrough compounds
HUE039734T2 (hu) 2012-05-29 2019-01-28 Parion Sciences Inc Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére
EP2867230B1 (en) 2012-07-02 2020-02-12 Monsanto Technology LLC Process for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
EP2914248B2 (en) 2012-11-02 2023-10-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
HK1209637A1 (en) 2012-12-13 2016-04-08 Novartis Ag Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
TWI695717B (zh) * 2014-03-06 2020-06-11 美商 Ptc 治療公司 １,２,４-二唑苯甲酸之鹽及醫藥組合物
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
RU2744460C2 (ru) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
CN106414443B (zh) 2014-06-03 2018-10-26 诺华股份有限公司 吡啶并嘧啶二酮衍生物
JP6343034B2 (ja) 2014-06-03 2018-06-13 ノバルティス アーゲー ナフチリジンジオン誘導体
JP6560257B2 (ja) 2014-06-03 2019-08-14 ノバルティス アーゲー ピリミド［４，５−ｂ］キノリン−４，５（３Ｈ，１０Ｈ）−ジオン誘導体
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
MA41051B1 (fr) 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
CN104292180A (zh) * 2014-10-12 2015-01-21 湖南华腾制药有限公司 一种恶二唑衍生物的制备方法
WO2016073470A1 (en) * 2014-11-04 2016-05-12 The University Of Kansas Lkb1-ampk activators for therapeutic use in polycystic kidney disease
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
CN107207488B (zh) * 2014-12-17 2020-11-17 伦敦皇家学院 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
CN108348527A (zh) * 2015-10-30 2018-07-31 Ptc医疗公司 用于治疗癫痫的方法
WO2017087364A1 (en) 2015-11-16 2017-05-26 Ptc Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxandiazole benzoic acid compounds, compositions and uses thereof
JP2019502753A (ja) 2015-12-23 2019-01-31 ムーンショット ファーマ エルエルシー ナンセンス変異依存ｍＲＮＡ分解機構の抑制による免疫応答の誘導法
TW201808922A (zh) 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
CN106279057B (zh) * 2016-08-15 2022-04-15 广州明药科技有限公司 Ataluren的合成方法
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
EP3512516A1 (en) 2016-09-13 2019-07-24 Marco Cipolli Method of treatment of shwachman-diamond syndrome
WO2018187479A1 (en) 2017-04-04 2018-10-11 Case Western Reserve University Method of modulating ribonucleotide reductase
EP3641752A4 (en) 2017-06-22 2021-03-17 Moonshot Pharma LLC METHOD OF TREATMENT OF CANCER WITH COMPOSITIONS WITH AMLEXANOX AND IMMUNE MODULATORS
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
WO2020078894A1 (en) 2018-10-15 2020-04-23 Academisch Medisch Centrum Oncotherapeutic combinations
KR102658031B1 (ko) * 2018-12-27 2024-04-18 제이투에이치바이오텍 (주) 근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체
EP4473971A3 (en) 2019-04-10 2025-02-19 PTC Therapeutics, Inc. Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients
CN110987847B (zh) * 2019-12-11 2021-02-19 苏州今蓝纳米科技有限公司 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用
CN111675672A (zh) * 2020-05-12 2020-09-18 石家庄市度智医药科技有限公司 一种制备阿塔鲁伦的方法
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
CN116217508B (zh) * 2022-12-15 2024-12-17 浙江工业大学 一类用于保护β细胞来治疗II型糖尿病的噁二唑类化合物及其制备方法和应用
US11932632B1 (en) 2023-10-13 2024-03-19 King Faisal University N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound
US11958814B1 (en) 2023-11-02 2024-04-16 King Faisal University 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound
CN119638642A (zh) * 2023-12-12 2025-03-18 暨南大学 双环类化合物及其药物组合物和应用
WO2025243250A1 (en) * 2024-05-23 2025-11-27 Biophore India Pharmaceuticals Pvt. Ltd. A process for the preparation of 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (no) * 1962-04-17
US3325446A (en) * 1964-04-17 1967-06-13 Allied Chem Stabilized halogen-containing olefin polymer compositions and stabilizers therefor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
JPS51143669A (en) 1975-06-06 1976-12-10 Takeda Chem Ind Ltd A process for preparing 1,2,4- oxadiazole derivatives
US4016170A (en) * 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4135910A (en) * 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4166732A (en) * 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4165910A (en) * 1977-10-25 1979-08-28 Bunker Ramo Corporation Electrical connector
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
DE3173083D1 (en) * 1980-03-22 1986-01-16 Fbc Ltd Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4320801A1 (de) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6071700A (en) * 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
US5970974A (en) 1995-03-14 1999-10-26 Siemens Aktiengesellschaft Dosating unit for an ultrasonic atomizer device
DE69605025T2 (de) 1995-03-14 2000-07-20 Siemens Ag Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit
WO1997009335A1 (en) 1995-09-07 1997-03-13 Novartis Ag Substituted phosphinic compounds and their use as pharmaceuticals
WO1997039745A1 (en) 1996-04-19 1997-10-30 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
WO1997041105A1 (en) * 1996-04-26 1997-11-06 Nippon Soda Co., Ltd. Novel heterocycle-substituted benzene derivatives and herbicides
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
CA2257206A1 (en) 1996-06-07 1997-12-11 Gui-Bai Liang Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
ES2329739T3 (es) 1997-04-07 2009-11-30 Georgetown University Analogos de cocaina.
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
WO1999021852A1 (en) * 1997-10-27 1999-05-06 Nippon Soda Co., Ltd. Novel benzoylpyrazole derivatives and herbicides
RO121834B1 (ro) 1998-03-16 2008-06-30 Inhale Therapeutic Systems, Inc. Dispozitiv pentru administrarea unui agent activ
NZ507696A (en) 1998-04-23 2003-10-31 Cortech Inc Triazole, oxadiazole and thiadiazole derivatives useful as cysteine protease inhibitors
CO5140073A1 (es) 1998-10-08 2002-03-22 Smithkline Beecham Plc Derivados de 2,3,4,5-tetrahidro-1h-3-benzapina
JP2002527438A (ja) 1998-10-09 2002-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４，５−ジヒドロ−イソオキサゾール誘導体及びそれらの製薬学的使用
AU1455500A (en) 1998-10-29 2000-05-22 Trega Biosciences, Inc. Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
WO2000038687A1 (en) 1998-12-23 2000-07-06 Smithkline Beecham Corporation Protease inhibitors
AU3196300A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
WO2000058278A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives d'acides amines $g(b)
WO2000058304A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
WO2000069810A1 (en) 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
JP2003528106A (ja) 2000-03-22 2003-09-24 メルク フロスト カナダ アンド カンパニー Ｐｔｐ−１ｂ阻害薬としての硫黄置換アリールジフルオロメチルホスホン酸類
AU2001248765A1 (en) * 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) * 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
DZ3347A1 (fr) 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
CN1328143A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人甲基化－dna－蛋白－半胱氨酸甲基转移酶13和编码这种多肽的多核苷酸
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
CN1516695A (zh) 2001-04-19 2004-07-28 用作抗病毒剂的芳基磺酰胺类化合物
KR20040004705A (ko) * 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
JP2003081832A (ja) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
MXPA05001592A (es) 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
KR100729883B1 (ko) 2003-03-28 2007-06-18 화이자 프로덕츠 인코포레이티드 죽상경화증 및 비만증을 치료하기 위한 ｃｅｔｐ억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체
EP4101846B1 (en) * 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
EP1799659A1 (en) 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
PL2402002T3 (pl) * 2005-04-08 2018-11-30 Ptc Therapeutics, Inc. Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop
EP2387995A1 (en) 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
UA99265C2 (ru) * 2006-09-08 2012-08-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)
NZ575795A (en) 2006-09-25 2012-03-30 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
MX2009003909A (es) 2006-10-12 2009-05-25 Ptc Therapeutics Inc Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora.
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
ES2622423T3 (es) 2007-10-04 2017-07-06 Merck Serono S.A. Derivados de oxadiazol
AU2008317566B2 (en) 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
WO2009079562A2 (en) 2007-12-17 2009-06-25 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
WO2010008831A2 (en) 2008-06-24 2010-01-21 Irm Llc Compounds and methods for modulating g protein-coupled receptors
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота

Also Published As

Publication number Publication date
ES2926542T3 (es) 2022-10-26
HK1257517A1 (en) 2019-10-25
ES2528195T3 (es) 2015-02-05
EP3889142B1 (en) 2022-06-15
EP3632902B1 (en) 2021-07-14
LU92698I2 (fr) 2015-06-22
US20100168109A1 (en) 2010-07-01
HK1214253A1 (en) 2016-07-22
SI2910551T1 (sl) 2017-07-31
HK1093979A1 (en) 2007-03-16
WO2004091502A2 (en) 2004-10-28
MXPA05010747A (es) 2006-05-25
CN1802360A (zh) 2006-07-12
US8299105B2 (en) 2012-10-30
NZ543263A (en) 2008-12-24
KR20060009838A (ko) 2006-02-01
JP4851933B2 (ja) 2012-01-11
US20110311486A1 (en) 2011-12-22
PL3549936T3 (pl) 2021-11-08
PL1618098T3 (pl) 2015-04-30
US7202262B2 (en) 2007-04-10
PT3632902T (pt) 2021-09-15
AU2004229487B9 (en) 2010-06-10
ES2881198T3 (es) 2021-11-29
SI3889142T1 (sl) 2022-10-28
SI3345895T1 (sl) 2020-03-31
US8796322B2 (en) 2014-08-05
SI1618098T1 (sl) 2015-04-30
EP2910551A1 (en) 2015-08-26
CY1125544T1 (el) 2024-09-20
CY1119001T1 (el) 2018-01-10
ES2770035T3 (es) 2020-06-30
NO2015002I2 (no) 2015-02-03
PL3632902T3 (pl) 2021-12-20
US8017636B2 (en) 2011-09-13
PL3345895T3 (pl) 2020-05-18
NO2015002I1 (no) 2015-02-16
WO2004091502A8 (en) 2005-11-24
EP3178816A1 (en) 2017-06-14
US7419991B2 (en) 2008-09-02
HK1202254A1 (en) 2015-09-25
CN1802360B (zh) 2014-05-07
CY2015017I2 (el) 2016-06-22
US8163782B2 (en) 2012-04-24
JP2011251981A (ja) 2011-12-15
DK1618098T3 (en) 2015-01-12
EP3889142A1 (en) 2021-10-06
PL3103800T3 (pl) 2018-11-30
US9861617B2 (en) 2018-01-09
PT3345895T (pt) 2020-01-29
US20100121070A1 (en) 2010-05-13
DK3889142T3 (da) 2022-09-12
EP3345895A1 (en) 2018-07-11
SI3632902T1 (sl) 2022-01-31
BRPI0409319B8 (pt) 2021-05-25
AU2004229487A1 (en) 2004-10-28
EP3632902A1 (en) 2020-04-08
DK3632902T3 (da) 2021-09-13
JP5436500B2 (ja) 2014-03-05
EP1618098A4 (en) 2008-07-16
EP1618098A2 (en) 2006-01-25
JP2006522826A (ja) 2006-10-05
US20040204461A1 (en) 2004-10-14
AU2004229487B2 (en) 2010-05-20
SI3103800T1 (sl) 2018-10-30
CN104056278B (zh) 2017-01-18
DK3549936T3 (da) 2021-07-12
CA2521992A1 (en) 2004-10-28
BRPI0409319A (pt) 2006-04-25
TR201706226T4 (tr) 2018-06-21
WO2004091502A3 (en) 2004-12-29
KR101134188B1 (ko) 2012-04-12
US8227494B2 (en) 2012-07-24
US20130289007A1 (en) 2013-10-31
US10071081B2 (en) 2018-09-11
HUE039026T2 (hu) 2018-12-28
US20070161687A1 (en) 2007-07-12
EP1618098B1 (en) 2014-11-19
PT3889142T (pt) 2022-08-22
ZA200508298B (en) 2007-01-31
UA84420C2 (ru) 2008-10-27
CA2521992C (en) 2013-02-05
US20120277234A1 (en) 2012-11-01
HUE047569T2 (hu) 2020-04-28
EP3103800B1 (en) 2018-06-13
US20100216851A1 (en) 2010-08-26
EA009120B1 (ru) 2007-10-26
HUE055434T2 (hu) 2021-11-29
US20050164973A1 (en) 2005-07-28
ES2679108T3 (es) 2018-08-22
US8129540B2 (en) 2012-03-06
BE2015C025I2 (no) 2023-08-09
CY1115870T1 (el) 2016-06-22
CY1124464T1 (el) 2022-07-22
PT3103800T (pt) 2018-07-27
PT1618098E (pt) 2015-02-10
ES2624610T3 (es) 2017-07-17
US7683082B2 (en) 2010-03-23
DK3345895T3 (da) 2020-02-03
CR8086A (es) 2006-12-19
US20060148863A1 (en) 2006-07-06
HUE031794T2 (en) 2017-08-28
PL2910551T3 (pl) 2017-09-29
PL3889142T3 (pl) 2022-09-26
US20180092887A1 (en) 2018-04-05
EA200501601A1 (ru) 2006-06-30
EP3103800A1 (en) 2016-12-14
PT3549936T (pt) 2021-07-14
PT2910551T (pt) 2017-05-22
CY1120446T1 (el) 2019-07-10
HUE059464T2 (hu) 2022-11-28
US20120178080A1 (en) 2012-07-12
IL171343A (en) 2013-06-27
US9205088B2 (en) 2015-12-08
US6992096B2 (en) 2006-01-31
IL225161A (en) 2014-03-31
US20060035943A1 (en) 2006-02-16
EP4101846B1 (en) 2023-08-02
SI3549936T1 (sl) 2021-09-30
US20160081988A1 (en) 2016-03-24
NO332843B1 (no) 2013-01-21
DK2910551T3 (en) 2017-05-15
EP3549936A1 (en) 2019-10-09
EP4101846A1 (en) 2022-12-14
US8486982B2 (en) 2013-07-16
NO20055314D0 (no) 2005-11-10
US7304080B2 (en) 2007-12-04
CY2015017I1 (el) 2016-06-22
EP3549936B1 (en) 2021-06-02
BRPI0409319B1 (pt) 2019-11-12
CN104056278A (zh) 2014-09-24
HUS1500021I1 (hu) 2017-04-28
DK3103800T3 (en) 2018-07-30
FR15C0030I1 (no) 2015-05-22
US20140301978A1 (en) 2014-10-09
ES2887054T3 (es) 2021-12-21
EP3345895B1 (en) 2019-12-04
HUE055056T2 (hu) 2021-10-28
EP2910551B1 (en) 2017-02-15
US20150148346A1 (en) 2015-05-28
US20060148864A1 (en) 2006-07-06
MA27802A1 (fr) 2006-03-01
CY1122659T1 (el) 2020-10-14
FR15C0030I2 (fr) 2015-07-24
US7772259B2 (en) 2010-08-10
US8975287B2 (en) 2015-03-10

Similar Documents

Publication Publication Date Title
NO20055314L (no) 1,2,4-oksadiazolbenzosyreforbindelser og deres anvendelse for nonsense supresjon og behandling av sykdom
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20060636L (no) Trisubstituerte aryl og heteroarylderivater som modulatorer av metabolisme og profylakse og behandling av lidelser relatert til dette
NO20083758L (no) Nye terapautiske kombinasjoner for behandling av depresjon
NO20074647L (no) 3,4 dihydro-1H-isoquinolin-2-karboksylsyre-5-ammopyridin-2-yl estere
NO20053846L (no) Fremgangsmate for a modifisere legemiddel-krystalldannelse
NO20091488L (no) Krystallinske former av 3-[5-(2-FHsorofenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
EA200900741A1 (ru) Способы лечения гиперхолестеринемии
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20060632L (no) Nye forbindelser og sammensettinger som omfatter steroler og/eller stanoler og kolesterolbiosynteseinhibitorer og anvendelse av disse i behandling eller forebygging av en rekke sykdommer og tilstander
DK1474406T3 (da) Disubstituerede thiazolylcarboxanilider samt deres anvendelse som mikrobicider
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
NO20083026L (no) Terapeutisk middel for diabetes
NO20045214L (no) Cyklotiokarbamatderivater som BR modulatorere og anvendelse derav for behandling av hudlidelser
CL2015001086A1 (es) Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
NO20051967L (no) 3,4-disubstituerte pyroler og deres anvendelse ved behandling av inflammatoriske sykdommer.
BRPI0607003A2 (pt) forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: TRANSLARNA; REG. NO/DATE: EU/1/13/902 20140812

Spc suppl protection certif: 2015002

Filing date: 20150203

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: TRANSLARNA; REG. NO/DATE: EU/1/13/902 20140812; FIRST REG. NO/DATE: EU/1/13/902 20140731

Spc suppl protection certif: 2015002

Filing date: 20150203

Extension date: 20290409